Document is current
Any future updates will be listed below
-
Authors
Shi, Haoshen
Yin, Zhuoran
Koronyo, Yosef
Fuchs, Dieu-Trang
Sheyn, Julia
Davis, Miyah R.
Wilson, Jered W.
Margeta, Milica A.
Pitts, Kristen M.
Herron, Shawn
Ikezu, Seiko
Ikezu, Tsuneya
Graham, Stuart L.
Gupta, Vivek K.
Black, Keith L.
Mirzaei, Mehdi
Butovsky, Oleg
Koronyo-Hamaoui, Maya http://orcid.org/0000-0003-2864-8442
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01 AG055865, R01 AG056478, R01 AG075998, R01 AG051812, R01 AG054672, 1R01AG075509)
Alzheimer's Association (Alzheimer's Association Research Fellowship to Promote Diversity)
Cure Alzheimer's Fund
BrightFocus Foundation (2020A016806)
National Institute of Neurological Disorders and Stroke (R01 NS088137, R21 NS104609, R21 NS101673)
National Eye Institute (R01 EY027921, EY016335, EY030160)
National Institute of General Medical Sciences (R01 GM132668)
American Glaucoma Society (American Glaucoma Society Young Clinician Scientist Award)
Research to Prevent Blindness (Research to Prevent Blindness Career Development Award)
- License Information
-
More Information
Article History
Received: 29 June 2022
Accepted: 29 August 2022
First Online: 8 September 2022
Declarations
:
: Experiments with mice were conducted in accordance with Harvard Medical School, Brigham and Women’s Hospital Institutional Animal Care and Use Committee (IACUC) guidelines under an approved protocol.
: Not applicable.
: O.B. is an inventor of a patent for use miR-155 inhibitors in neurodegenerative diseases. O.B. and M.A.M. are co-inventors of a patent for use of Galectin-3 inhibitors for treatment of glaucoma. O.B.: collaboration with Sanofi, GSK, Regulus Therapeutics; research funding from Sanofi, GSK, miRagen Therapeutics, honoraria for lectures, consultancy: Camp4.
